{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:00:53Z","timestamp":1785499253424,"version":"3.56.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Despite major advances in targeted therapy and immune checkpoint blockade, advanced NSCLC still has poor long-term outcomes. Only a minority of patients achieve durable benefit, and many eventually experiencing disease progression. Local ablation techniques, particularly cryoablation, directly destroy tumors and remodel the local immune microenvironment by inducing immunogenic cell death and releasing tumor antigens and damage-associated molecular patterns (DAMPs). These processes may contribute to systemic antitumor immunity and are associated with a more inflamed tumor immune microenvironment. This review summarizes the biological mechanisms underlying the potential synergy between cryoablation and immunotherapy, particularly immune checkpoint inhibitors. Cryoablation has been proposed to act as an\n                    <jats:italic>in situ<\/jats:italic>\n                    vaccination strategy by preserving native tumor antigens and enhancing antigen presentation and T-cell priming. These effects may in turn trigger systemic antitumor immune responses beyond the treated site. The article summarizes preclinical and clinical evidence supporting this combined approach. Available studies suggest that cryoablation combined with immunotherapy may improve tumor control and survival outcomes in selected NSCLC settings. However, current clinical evidence remains heterogeneous and is still limited in scale. Finally, we discuss key challenges, including treatment sequencing, biomarker development, technical standardization, and long-term safety, and outline future directions for prospective and biomarker-informed clinical studies. This review highlights the potential role of cryoablation as an adjunct to immunotherapy in selected NSCLC settings, while emphasizing the need for further prospective validation.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1869239","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:35:40Z","timestamp":1785497740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers"],"prefix":"10.3389","volume":"16","author":[{"given":"Chulan","family":"Yang","sequence":"first","affiliation":[{"name":"Central Laboratory, Guangzhou Fuda Cancer Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangzhou Fuda Cancer Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ma","sequence":"additional","affiliation":[{"name":"Central Laboratory, Guangzhou Fuda Cancer Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangzhou Fuda Cancer Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2363","article-title":"Advances in systemic therapy for non-small cell lung cancer","volume":"375","author":"Miller","year":"2021","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17425247.2021.1825377","article-title":"Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-part I","volume":"18","author":"Upadhya","year":"2021","journal-title":"Expert Opin Drug Delivery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217272","article-title":"Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma","volume":"604","author":"Huang","year":"2024","journal-title":"Cancer Lett"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70261-6","article-title":"Cryosurgery updated","volume":"31","author":"Kuflik","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13111114","article-title":"In situ vaccination by tumor ablation: Principles and prospects for systemic antitumor immunity","volume":"13","author":"Chikovani","year":"2025","journal-title":"Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100849","article-title":"A phase I dose-escalation clinical trial of bronchoscopic cryoimmunotherapy in advanced-stage NSCLC","volume":"6","author":"Tsay","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14551","article-title":"An oldest\u2010old non\u2010small cell lung cancer patient with abscopal effect in a single lesion","volume":"13","author":"Sakaguchi","year":"2022","journal-title":"Thorac Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2019.1647355","article-title":"Cryoablation: physical and molecular basis with putative immunological consequences","volume":"36","author":"Baust","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050365","article-title":"Cryoablation and immunotherapy: An enthralling synergy for cancer treatment","volume":"30","author":"Medlej","year":"2023","journal-title":"Curr Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2020.01.006","article-title":"Cryoablation and immunotherapy of cancer","volume":"65","author":"Yakkala","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2010.11.008","article-title":"Thermal ablation of lung tumors","volume":"20","author":"Sonntag","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S197406","article-title":"Cryoablation in the management of breast cancer: Evidence to date","volume":"11","author":"Pusceddu","year":"2019","journal-title":"Breast Cancer: Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.tvir.2007.08.005","article-title":"Cryoablation for liver cancer","volume":"10","author":"Hinshaw","year":"2007","journal-title":"Tech Vasc Interv Radiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1464-410X.2010.09235.x","article-title":"Current state of urological cryosurgery: prostate and kidney","volume":"105","author":"Levy","year":"2010","journal-title":"BJU Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000020091","article-title":"Current status of minimally invasive treatment options for localized prostate carcinoma","volume":"37","author":"Beerlage","year":"2000","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2009.12.403","article-title":"Cryoablation: Mechanism of action and devices","volume":"21","author":"Erinjeri","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13244-019-0727-5","article-title":"Cryoablation and immunotherapy: an overview of evidence on its synergy","volume":"10","author":"Aarts","year":"2019","journal-title":"Insights Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11548-019-02051-8","article-title":"GPU-based 3D iceball modeling for fast cryoablation simulation and planning","volume":"14","author":"Golkar","year":"2019","journal-title":"Int J Comput Assist Radiol Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/end.2009.0587","article-title":"The effect of argon gas pressure on ice ball size and rate of formation","volume":"24","author":"Sprenkle","year":"2010","journal-title":"J Endourol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2006.11.006","article-title":"A history of cryosurgery: its development and future","volume":"204","author":"Korpan","year":"2007","journal-title":"J Am Coll Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"107871","DOI":"10.1016\/j.jvir.2025.10.004","article-title":"Cryoablation protocols for primary and metastatic lung tumors: a systematic review and meta-analysis evaluating effectiveness and safety of percutaneous cryoablation of pulmonary tumors","volume":"37","author":"Sarshoghi","year":"2026","journal-title":"J Vasc Interv Radiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","article-title":"Thermal ablation of tumours: biological mechanisms and advances in therapy","volume":"14","author":"Chu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2013.11.001","article-title":"Mechanisms of cryoablation: Clinical consequences on Malignant tumors","volume":"68","author":"Baust","year":"2014","journal-title":"Cryobiology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1006\/cryo.1998.2115","article-title":"Mechanisms of tissue injury in cryosurgery","volume":"37","author":"Gage","year":"1998","journal-title":"Cryobiology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-55382011000600002","article-title":"Biophysiologic considerations in cryoablation: a practical mechanistic molecular review","volume":"37","author":"Maccini","year":"2011","journal-title":"Int Braz J Urol Off J Braz Soc Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2008.10.126","article-title":"Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses","volume":"58","author":"Sabel","year":"2009","journal-title":"Cryobiology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.950921","article-title":"Cryoablation and immune synergistic effect for lung cancer: a review","volume":"13","author":"Tian","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24105","article-title":"Cryoablation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"10","author":"Yang","year":"2019","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1326441","article-title":"Characterization of the cryoablation-induced immune response in kidney cancer patients","volume":"6","author":"Kato","year":"2017","journal-title":"OncoImmunology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/thno.67530","article-title":"Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation","volume":"12","author":"Kwak","year":"2022","journal-title":"Theranostics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12880-023-01110-6","article-title":"The safety and response of CT guided percutaneous cryoablation for lung nodules by 17-gauge needles","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Med Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2024-2228","article-title":"Comparison of the efficacy and adverse events between argon-helium cryoablation and microwave ablation for non-small cell lung cancer: a propensity score matching study","volume":"17","author":"Nan","year":"2025","journal-title":"J Thorac Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13068","article-title":"Safety and efficacy of thermal ablation for subpleural lung cancers","volume":"10","author":"Cao","year":"2019","journal-title":"Thorac Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-296","article-title":"Safety and efficacy of co-ablation vs. microwave ablation in the treatment of subpleural stage I non-small cell lung cancer: a comparative study","volume":"17","author":"Wang","year":"2025","journal-title":"J Thorac Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2012.07.13","article-title":"Cryosurgery for lung cancer","volume":"4","author":"Niu","year":"2012","journal-title":"J Thorac Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106031","article-title":"Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study","volume":"11","author":"Peters","year":"2026","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036863","article-title":"New approaches on cancer immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"De Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: The phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112151-20230922-00203","article-title":"Chinese expert consensus on clinical detection of PD-L1 expression in non-small cell lung cancer (2023 edition)","volume":"53","year":"2024","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13488","article-title":"Immunotherapy as second\u2010line treatment and beyond for non\u2010small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real\u2010world retrospective analysis","volume":"11","author":"Chen","year":"2020","journal-title":"Thorac Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000251","article-title":"EGFR mutations in Asian patients with advanced lung adenocarcinoma","volume":"9","author":"Liam","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8927-x","article-title":"Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer","volume":"65","author":"Lin","year":"2017","journal-title":"Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0731-8","article-title":"Emerging therapies for non-small cell lung cancer","volume":"12","author":"Zhang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930461","article-title":"Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1075","article-title":"Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors","volume":"10","author":"Rangamuwa","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008386","article-title":"Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer","volume":"12","author":"Gu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cryobiol.2008.06.003","article-title":"Immunologic response to primary cryoablation of high-risk prostate cancer","volume":"57","author":"Si","year":"2008","journal-title":"Cryobiology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25601","article-title":"Analysis of tumor antigen\u2010specific T cells and antibodies in cancer patients treated with radiofrequency ablation","volume":"128","author":"Widenmeyer","year":"2011","journal-title":"Int J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1804711","article-title":"Defining the abscopal effect in non-small cell lung cancer in the era of immunotherapy and lung ablation treatment: a narrative review","volume":"13","author":"Smesseim","year":"2026","journal-title":"Front Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2025.2525444","article-title":"Cryoablation combined with programmed cell death protein 1 (PD-1) inhibitors regulates myeloid-derived suppressor cells (MDSCs) through the JAK2-STAT3-S100A8\/A9 axis in mice with Lewis lung carcinoma","volume":"42","author":"Li","year":"2025","journal-title":"Int J Hyperthermia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167262","article-title":"Combined cryoablation and PD-1 inhibitor synergistically enhance antitumor immune responses in Lewis lung adenocarcinoma mice via the PI3K\/AKT\/mTOR pathway","volume":"1870","author":"Liu","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2023.10.002","article-title":"Combining local cryoablation with PD-L1 blockade synergistically eradicates established murine lung cancer by modulating mitochondrial in PD-1+CD8+ T cell","volume":"263","author":"Zhai","year":"2023","journal-title":"Immunol Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1520-4","article-title":"Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity","volume":"63","author":"Alteber","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2422","article-title":"Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity","volume":"11","author":"Machlenkin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.898194","article-title":"The application of cytidyl guanosyl oligodeoxynucleotide can affect the antitumor immune response induced by a combined protocol of cryoablation and dendritic cells in Lewis lung cancer model","volume":"22","author":"Zhang","year":"2016","journal-title":"Med Sci Monit"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1159\/000545185","article-title":"Cryoablation combined with programmed cell death protein 1 inhibitor pembrolizumab for advanced non-small cell lung cancer","volume":"70","author":"Wang","year":"2025","journal-title":"Chemotherapy"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.62347\/MBFJ9966","article-title":"PD-1 inhibitor therapy combined with argon-helium cryoablation is effective against non-small cell lung cancer","volume":"17","author":"Chen","year":"2025","journal-title":"Am J Transl Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2013.08.001","article-title":"Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer","volume":"67","author":"Yuanying","year":"2013","journal-title":"Cryobiology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.44215","article-title":"Efficacy of argon\u2013helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer","volume":"64","author":"Zheng","year":"2025","journal-title":"Acta Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-025-02460-z","article-title":"Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1\/L1 therapy (BOOSTER): a randomized phase 2 trial","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15020201","article-title":"Early effects of bronchoscopic cryotherapy in metastatic non-small cell lung cancer patients receiving immunotherapy: a single-center prospective study","volume":"15","author":"Vasiliauskas","year":"2025","journal-title":"Diagnostics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1013047","article-title":"Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: a case report and literature review","volume":"12","author":"Nian","year":"2022","journal-title":"Front Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100737","article-title":"CRYOVATE: a pilot study of lung cancer cryoactivation in combination with immunotherapy in advanced NSCLC","volume":"5","author":"Desilets","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1185291","article-title":"Argon-helium knife cryoablation plus programmed cell death protein 1 inhibitor in the treatment of advanced soft tissue sarcomas: there is no evidence of the synergistic effects of this combination therapy","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2021.07.007","article-title":"The clinical efficacy of argon-helium knife cryoablation combined with nivolumab in the treatment of advanced non-small cell lung cancer","volume":"102","author":"Feng","year":"2021","journal-title":"Cryobiology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050855","article-title":"Thermal ablation combined with immune checkpoint blockers: a 10-year monocentric experience","volume":"16","author":"Bonnet","year":"2024","journal-title":"Cancers"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2026.2651072","article-title":"The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives","volume":"18","author":"Perez","year":"2026","journal-title":"Immunotherapy"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1177\/147323001103900516","article-title":"Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer","volume":"39","author":"Gu","year":"2011","journal-title":"J Int Med Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033223","article-title":"Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer","volume":"7","author":"Yamauchi","year":"2012","journal-title":"PloS One"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2023.10.033","article-title":"Synergizing thermal ablation modalities with immunotherapy: enough to induce systemic antitumoral immunity","volume":"35","author":"Mustafa","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203539","article-title":"Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy","volume":"14","author":"Velez","year":"2023","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349411","article-title":"Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease","volume":"42","author":"Mittendorf","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15534","article-title":"Circulating tumor DNA detection for recurrence monitoring of stage I non\u2010small cell lung cancer treated with microwave ablation","volume":"16","author":"Cheng","year":"2025","journal-title":"Thorac Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.01.017","article-title":"Immunological aspects of cryoablation of non\u2013small cell lung cancer: a comprehensive review","volume":"13","author":"Katzman","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.14336\/AD.2022.0407","article-title":"Tumor immune microenvironment and immunotherapy in non-small cell lung cancer: update and new challenges","volume":"13","author":"Xing","year":"2022","journal-title":"Aging Dis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70196","article-title":"Immune checkpoint molecules: a review on pathways and immunotherapy implications","volume":"13","author":"Rezazadeh\u2010Gavgani","year":"2025","journal-title":"Immun Inflammation Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2020.09.014","article-title":"Thermal ablation, embolization, and selective internal radiation therapy combined with checkpoint inhibitor cancer immunotherapy: safety analysis","volume":"32","author":"Leppelmann","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.17.18368","article-title":"The role of percutaneous image-guided thermal ablation for the treatment of pulmonary Malignancies","volume":"209","author":"Mouli","year":"2017","journal-title":"Am J Roentgenol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13419","article-title":"Image\u2010guided percutaneous microwave ablation of early\u2010stage non\u2013small cell lung cancer","volume":"16","author":"Ni","year":"2020","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1869239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:35:44Z","timestamp":1785497744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1869239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":102,"alternative-id":["10.3389\/fonc.2026.1869239"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1869239","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1869239"}}